• Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer

  NCT04701281

  TerminatedInterventionalPhase 1Phase 2Updated Sep 18, 2025
• Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure

  NCT01348412

  CompletedInterventionalPhase 2Updated Jul 16, 2018
• FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer

  NCT04430985

  WithdrawnInterventionalPhase 2Updated Oct 27, 2021
• Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

  NCT00513266

  Unknown statusInterventionalPhase 2Updated Aug 7, 2009
• Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

  NCT02345746

  WithdrawnInterventionalPhase 2Updated Aug 24, 2017
• Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

  NCT00006050

  CompletedInterventionalPhase 2Updated Feb 17, 2021

ClinicalTrials.gov ID

NCT02885753

Lead Sponsor

Federation Francophone de Cancerologie DigestiveOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

348Estimated

Last Update Posted

Jul 9, 2025Actual

Start Date

Dec 2016Actual

Primary Completion Date

Sep 2028Estimated

Completion Date

Sep 2028Estimated

Official Title

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Brief Summary

Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases. Surgical resection of these metastases, only curative treatment is not immediately possible in 10-15% of cases. In unresectable patients, current palliative treatments are based on systemic chemotherapy associated or not with the targeted therapies (anti-EGFR (panitumumab), anti-VEGF (bevacizumab)). In this patient population, special attention was paid to intensified treatment regimens in order to improve their efficiency and improving the tumoral response rate, the intensity of the response and its earliness correlate with improved overall and progression-free survival.

The intra-arterial use of oxaliplatin coupled with IV chemotherapy has yielded OR levels of 64% in patients having survived one or more lines of chemotherapy IV and 62% in patients who have progressed on oxaliplatin IV. In addition, the HIA administration of oxaliplatin limits systemic and especially neurological toxicities, thanks to a greater hepatic clearance.

In conclusion, the combination of systemic chemotherapy, targeted therapy and HIAC with oxaliplatin has showed promising efficacy results associated with good tolerance from the first line onwards. Indeed, we can expect from the Phase II recent data, a control rate close to 100%, with high response rates associated with early maturity and depth responses as well as prolonged survival. However, to date, in the absence of randomized trial testing this combination, this strategy does not have sufficient evidence to be integrated in our routine practices, and HIAC remains limited to a few expert centers in treatment catch-up.

• Colorectal Neoplasms

• Oxaliplatin intravenous
• 5 FU bolus
• Folinic acid
• Oxaliplatin intra-arteriel
• Panitumumab
• Bevacizumab
• 5 FU continuous
• Irinotecan

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Histologically proven colorectal adenocarcinoma with hepatic metastasis(es)
• At least one measurable hepatic metastasis according to the criteria RECIST v1.1
• No other metastatic sites except lung nodules if number ≤ 3 and < 10 mm
• RAS mutation status known (determination of KRAS mutation (exons 2,3 and 4) and determination of the NRAS mutation (exons 2,3 and 4))
• Age ≥ 18
• WHO ≤ 2 (Appendix 4)
• No prior treatment by chemotherapy except perioperative or adjuvant chemotherapy discontinued for more than 12 months
• Life expectancy > 3 months
• PNN > 1500/mm3, platelets > 100 000/mm3, Hb > 9 g/dLq
• Bilirubin < 25 mmol/L, AST < 5x ULN, ALT < 5 x ULN, ALP < 5 x ULN, TP > 60%, proteinuria from 24H < 1 g
• Creatinine clearance > 50 mL/min according to MDRD formula (Appendix 4)
• Patient affiliated to a social security scheme
• Patient information and signature of the informed consent

Exclusion Criteria:

• Contraindications specific to the installation of a KTHIA: thrombosis of the hepatic artery, arterial vascular anatomy may compromise a secondary hepatic resection.
• Patient immediately eligible for a curative therapy (surgical and/or percutaneous) after discussion in CPR
• Following alterations in the 6 months prior to inclusion: myocardial infarction, angina, severe/unstable angina, coronary artery bypass surgery, congestive heart failure NYHA class II, III or IV, stroke or transient ischemic attack
• Hypertension not controlled by medical treatment (SBP > 140 mmHg and/or DBP> 90 mmHg with blood pressure taken according to the diagram of the HAS)
• A history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding in the 6 months preceding the start of treatment
• Progressive gastroduodenal ulcer, wound or fractured bone
• Abdominal or major extra-abdominal surgery (except diagnostic biopsy) or irradiation in the 4 weeks before starting the treatment
• Transplant patients, HIV positive or other immune deficiency syndromes
• Any progressive pathology not balanced over the past 6 months: hepatic failure, renal failure, respiratory failure
• Peripheral neuropathy > 1
• Patient with interstitial pneumonitis or pulmonary fibrosis
• History of chronic diarrhea or inflammatory disease of the colon or rectum, or unresolved occlusion or sub-occlusion in symptomatic treatment
• History of malignant pathologies during the past 5 years except basocellular skin carcinoma considered in complete remission or in situ cervical carcinoma, properly treated
• Patient already included in another clinical trial with an experimental molecule
• Any known specific contraindication or allergy or hypersensitivity to the drugs used in the study (cf RCP Appendix 7)
• Known deficit in DPD
• QT/QTc range > 450 msec for men and > 470 msec for women
• K+ < LNL, Mg2+ < LNL, Ca2+ < LNL
• Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women, women of childbearing age not having had a pregnancy test
• Persons deprived of liberty or under supervision
• Impossibility of undergoing medical monitoring during the trial for geographic, social or psychological reasons

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Federation Francophone de Cancerologie DigestiveOTHER

anbouvier@chu-angers.fr02 41 35 35 03

faudemar@ch-cotebasque.fr0559443722

edith.carton@icrb.fr02 90 09 44 66

basmahane@gmail.com01 46 25 28 64